Literature DB >> 12065620

Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3beta.

Fumiko Mukai1, Koichi Ishiguro, Yumiko Sano, Shinobu C Fujita.   

Abstract

Glycogen synthase kinase 3 (GSK3) plays important roles in Wnt and insulin signaling, cell fate determination, and Alzheimer-like tau phosphorylation. We discovered an isoform of tau protein kinase I (TPKI)/GSK3beta with a 13 amino acid insert in the catalytic domain owing to alternative splicing. The alternative transcripts were found in the brains of the mouse, rat and human, with highly conserved sequences. The variant protein, named TPKI2/GSK3beta2, was abundant in the brain. Immunohistochemistry indicated differential distribution of the conventional and the new TPKI/GSK3beta isoforms within young neurons. TPKI2/GSK3beta2 showed decreased kinase activities towards two phosphorylation sites on tau compared with the conventional isoform. Immunohistochemistry indicated that TPKI2/GSK3beta2 occurs predominantly in the neuronal soma, while TPKI1/GSK3beta1 is found both in the soma and processes. These results indicate that the new splice isoform has a different function. Because the amino acid insert occurs in the domain implicated in interaction with a protein phosphatase in a homologous kinase cdk-2, the alternative splicing can regulate multiprotein complex formation and function involving TPKI/GSK3beta.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12065620     DOI: 10.1046/j.1471-4159.2002.00918.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  66 in total

Review 1.  GSK-3: tricks of the trade for a multi-tasking kinase.

Authors:  Bradley W Doble; James R Woodgett
Journal:  J Cell Sci       Date:  2003-04-01       Impact factor: 5.285

Review 2.  GSK3 signalling in neural development.

Authors:  Eun-Mi Hur; Feng-Quan Zhou
Journal:  Nat Rev Neurosci       Date:  2010-08       Impact factor: 34.870

Review 3.  Glycogen synthase kinase 3: a point of convergence for the host inflammatory response.

Authors:  Huizhi Wang; Jonathan Brown; Michael Martin
Journal:  Cytokine       Date:  2010-11-23       Impact factor: 3.861

Review 4.  Targeting glycogen synthase kinase-3 (GSK-3) in the treatment of Type 2 diabetes.

Authors:  Katrina MacAulay; James R Woodgett
Journal:  Expert Opin Ther Targets       Date:  2008-10       Impact factor: 6.902

Review 5.  Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases.

Authors:  Eleonore Beurel; Steven F Grieco; Richard S Jope
Journal:  Pharmacol Ther       Date:  2014-11-27       Impact factor: 12.310

Review 6.  Physiological roles of glycogen synthase kinase-3: potential as a therapeutic target for diabetes and other disorders.

Authors:  J R Woodgett
Journal:  Curr Drug Targets Immune Endocr Metabol Disord       Date:  2003-12

7.  GSK3beta mediates renal response to vasopressin by modulating adenylate cyclase activity.

Authors:  Reena Rao; Satish Patel; Chuanming Hao; James Woodgett; Raymond Harris
Journal:  J Am Soc Nephrol       Date:  2010-01-07       Impact factor: 10.121

8.  Co-localization of glycogen synthase kinase-3 with neurofibrillary tangles and granulovacuolar degeneration in transgenic mice.

Authors:  Takashi Ishizawa; Narahiko Sahara; Koichi Ishiguro; Jay Kersh; Eileen McGowan; Jada Lewis; Michael Hutton; Dennis W Dickson; Shu-Hui Yen
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

9.  GSK-3β polymorphism discriminates bipolar disorder and schizophrenia: a systematic meta-analysis.

Authors:  Hui Tang; Na Shen; Huijuan Jin; Dan Liu; Xiaoping Miao; Ling-Qiang Zhu
Journal:  Mol Neurobiol       Date:  2013-02-27       Impact factor: 5.590

Review 10.  GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder.

Authors:  Michael K Rowe; Charlotte Wiest; De-Maw Chuang
Journal:  Neurosci Biobehav Rev       Date:  2007-03-15       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.